TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371	Attorney Docket No. 0508-1160
	U.S. Application No. 10/577658

INTERNATIONAL APPLN. NO. PCT/FR2004/002797	INTERNATIONAL FILING DATE October 29, 2004	PRIORITY DATE CLAIMED October 30, 2003

TITLE OF INVENTION: NOVEL PHOSPHATE-BINDING PROTEIN, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF

APPLICANT(S) FOR DO/EO/US: Eric CHABRIERE; Carlos CONTRERAS-MARTEL; Juan FONTECILLA-CAMPS

Applicant herewith submits to the United States Designated Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
   a. ☒ is attached hereto (required only if not communicated by the International Bureau).
   b. ☐ has been communicated by the International Bureau. See attached PCT/IB/308.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2))
   a. ☒ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made, however, the time limit for making such amendments has NOT expired.
   d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))
10. ☐ A Declaration of Inventorship for purposes of U.S.A. designation pursuant to rule 4.17(iv).))
11. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

   Items 12 to 23 below concern document(s) or information included:

12. ☒ Information Disclosure Statement (IDS) w/PTO-1449 - ☒ Copy of IDS citations. - ☒ PCT/ISA/210 International Search Report included
13. ☐ Assignment Papers (cover sheet & document(s)).
14. ☒ A preliminary amendment.
15. ☒ An Application Data Sheet under 37 C.F.R. 1.76.
16. ☒ Itemized Return Receipt Postcard
17. ☒ Abstract
18. ☐ A substitute specification.
19. ☐ Power of Attorney and Statement under 37 CFR §3.73(b)
   a. ☐ Newly executed Power of Attorney
   b. ☐ A change of Power of Attorney and/or change of address letter.
20. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13*ter*.2 and 37 CFR 1.821 - 1.825.
21. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
22. ☐ A second copy of the English language translation of the international application (35 U.S.C. 154(d)(4)).
23. ☒ Other items or information: **SUBMISSION UNDER 37 C.F.R. §1.821 FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (PAPER SEQUENCE LISTING)**

Y & T May 1, 2006

U.S. APPLICATION NO. **10/577658**	INTERNATIONAL APPLN. NO. PCT/FR2004/002797	ATTORNEY DOCKET NO. 0508-1160

	CALCULATIONS PTO USE ONLY

☐ **Applicant claims small entity status. See 37 CFR 1.27.**

☒ The following fees are submitted:

PCT FEES - NATIONAL STAGE

Fee Description

	Basic National Stage Fee	$300.00	
Non ISA/US Search Provided	National Stage Search Fee	$400.00	
☐ US was the IPEA **And** all claims satisfied the provisions of PCT Article 33 (1)-(4)	National Stage Examination Fee	$200.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20- ☒ 30 months from the earliest claimed priority date (Fee Code 1617/2617)		$130.00	

National Stage Application size fee each additional 50 sheets in excess of 100 Fee Code 1681/2681	Additional Sheets - 100 = ____ = ____ X ‾‾50‾‾	Fee From Below $125.00	$0.00	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Independent Claims Fee Codes 1614 / 2614	2 - 3 =	0	X $100.00	$0.00	
Total Claims Fee Codes 1615 / 2615	17 - 20 =	0	X $25.00	$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) Fee Code 1616 / 2616			+ $360.00	$0.00	
Processing fee of $130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).Fee Code 1618				$0.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). (Fee code 8021) $40.00 per property			+	$0.00	
		TOTAL FEES ENCLOSED =		$1,030.00	
				Amount to be refunded:	$
				Charged:	$

☒ A check in the amount of **$1,030.00** to cover the above fees is attached.

☐ The Director is hereby authorized to charge indicated fees and credit any overpayment to Deposit Account No. 25-0120 in the name of Young & Thompson. A duplicate copy of this sheet is enclosed.

☒ The Director is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17.

SEND ALL CORRESPONDENCE TO:
YOUNG & THOMPSON
745 South 23rd Street
Arlington, VA 22202
Telephone: (703) 521-2297
Facsimile: (703) 685-0573

Y&T Customer No. **00466**

BC/**mps**

/SIGNATURE/

Benoit Castel, Reg. No. 35,041
NAME, REGISTRATION NUMBER

May 1, 2006
DATE

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re application of

Eric CHABRIERE et al.   Conf.

Application No. NEW NATIONAL PHASE Group

Filed May 1, 2006   Examiner

NOVEL PHOSPHATE-BINDING PROTEIN, PHARMACEUTICAL COMPOSTIOIONS
CONTAINING SAME AND USE THEREOF

SUBMISSION UNDER 37 C.F.R. §1.821
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents   May 1, 2006
P.O. Box 1450
Alexandria, VA   22313-1450

Sir:

    Applicant(s) attach(es) to the present paper a

"Sequence Listing", as required by Rule 821(c).

    Respectfully submitted,

YOUNG & THOMPSON

Benoit Castel

Benoit Castel, Reg. No. 35,041
745 South 23rd Street
Arlington, VA   22202
Telephone (703) 521-2297
Telefax (703) 685-0573
         (703) 979-4709

BC/mps